RNAZ logo

TransCode Therapeutics (RNAZ)

Profile

Full Name

TransCode Therapeutics, Inc.

Ticker Symbol

RNAZ

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

July 8, 2021

Indexes

Not included

Website

http://www.transcodetherapeutics.com

Employees

8

Key Details

Price

$0.41(+1.49%)

Market cap

$285.44K(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$3419.13(+90.44% YoY)

PE ratio

-

Next earnings date

N/A

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.41
RNAZ price is $0.41

30-Day Relative Volume

0.14
RNAZ 30-day relative volume is 0.14

Price Performance

Price Most recent change

+1.49%
RNAZ price was up +1.49% on Apr 14, 2025

Price YTD change

-87.83%
RNAZ price is down -87.83% since January 1st

Price 1-year change

-98%
RNAZ price is down -98% year-on-year

Price 3-year change

-100%
RNAZ price is down -100% over the past 3 years

Price Range

Price All-time high

$170280.00
RNAZ price is currently -100.00% below its historical high of $170280.00

Price 3-year low

$0.22
RNAZ price is currently +89.81% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$285.44K
RNAZ market capitalization is $285.44 thousand

Market cap 3-year change

-99.25%
RNAZ market capitalization is down -99.25% over the past 3 years

Market cap All-time high

$85.14M
RNAZ market capitalization is currently -99.66% below its historical high of $85.14 million

Market cap sector rank

2.63%
RNAZ market capitalization is higher than 2.63% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+295.57%
RNAZ shares outstanding is up +295.57% year-on-year

Shares Outstanding 3-Year Change

+139140%
RNAZ shares outstanding is up +139140% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.46
RNAZ beta is 1.46

200-day SMA

$10.58
RNAZ price is currently -96.12% below its 200-day simple moving average

50-day SMA

$3.62
RNAZ price is currently -88.69% below its 50-day simple moving average

RSI

27.95
RNAZ 14-day relative strength index is 27.95

Volume

0.14
RNAZ 30-day relative volume is 0.14

ATR

$0.28
RNAZ average true range is $0.28

10-day Historical Volatility

108.90%
RNAZ 10-day historical volatility is 108.90%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
RNAZ annual revenue value is unknown

Revenue Analysts estimate

$300.00K
RNAZ annual revenue is currently equal to the consensus analysts' forecast

Revenue 1-year change

-
RNAZ annual revenue 1-year change is unknown

Revenue Sector rank

-
RNAZ annual revenue is unknown

EPS

EPS

-$3419.13
RNAZ annual earnings per share is -$3419.13

EPS Analysts estimate

-$4.76
RNAZ annual earnings per share is currently >+9900.00% higher than the consensus analysts' forecast

EPS 1-year change

+90.44%
RNAZ annual earnings per share is up +90.44% year-on-year

EPS Sector rank

0.33%
RNAZ annual earnings per share is higher than 0.33% of companies in Healthcare sector

Profit

Gross profit

-
RNAZ annual gross profit value is unknown

Gross margin

-
RNAZ annual gross profit margin value is unknown

Operating profit

-$18.50M
RNAZ annual operating income is -$18.50 million

Operating margin

-
RNAZ annual operating profit margin value is unknown

Net income

-$18.55M
RNAZ annual net profit is -$18.55 million

Net margin

-
RNAZ annual net profit margin value is unknown

Expenses

Total expenses

$18.50M
RNAZ annual total expenses is $18.50 million

Operating expenses

$18.50M
RNAZ annual total operating expenses is $18.50 million

Cost of goods sold

-
RNAZ annual cost of goods sold value is unknown

Selling, general & administrative expenses

$7.16M
RNAZ annual SGA is $7.16 million

Depreciation and amortization

$516.70K
RNAZ annual depreciation & amortization is $516.70 thousand

Interest expense

$55.90K
RNAZ annual interest expense is $55.90 thousand

Income tax

-
RNAZ annual income tax value is unknown

EBIT & EBITDA

EBIT

-$18.49M
RNAZ annual earnings before interest & taxes is -$18.49 million

EBITDA

-$17.97M
RNAZ annual EBITDA is -$17.97 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$5.17M
RNAZ annual total assets is $5.17 million

Non current assets

$714.30K
RNAZ annual long term assets is $714.30 thousand

Current assets

$4.46M
RNAZ annual total current assets is $4.46 million

Cash and cash equivalents

$2.77M
RNAZ annual cash & cash equivalents is $2.77 million

Accounts receivable

-
RNAZ annual accounts receivable value is unknown

Inventory

-
RNAZ annual inventory value is unknown

Liabilities

Total liabilities

$3.53M
RNAZ annual total liabilities is $3.53 million

Long term liabilities

$38.30K
RNAZ annual total long term liabilities is $38.30 thousand

Current liabilities

$3.49M
RNAZ annual total current liabilities is $3.49 million

Accounts payable

-
RNAZ annual accounts payable value is unknown

Debt

Total debt

$450.60K
RNAZ annual total debt is $450.60 thousand

Total debt 1-year change

+100%
RNAZ annual total debt is up +100% year-on-year

Long term debt

$38.30K
RNAZ annual long term debt is $38.30 thousand

Short term debt

$412.30K
RNAZ annual short term debt is $412.30 thousand

Equity & Capital

Shareholders equity

$1.64M
RNAZ annual stockholders equity is $1.64 million

Book value

$1.64M
RNAZ annual book value is $1.64 million

Retained earnings

-$46.42M
RNAZ annual retained earnings is -$46.42 million

Working capital

$964.80K
RNAZ annual working capital is $964.80 thousand

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$18.07M
RNAZ annual cash flow from operations is -$18.07 million

Cash from operations 1-year change

-14.67%
RNAZ annual cash flow from operations is down -14.67% year-on-year

Cash from investing

-$35.60K
RNAZ annual cash flow from investing activities is -$35.60 thousand

Cash from investing 1-year change

+64.72%
RNAZ annual cash flow from investing activities is up +64.72% year-on-year

Cash from financing

$15.91M
RNAZ annual cash flow from financing activities is $15.91 million

Cash from financing 1-year change

+265055%
RNAZ annual cash flow from financing activities is up +265055% year-on-year

CAPEX

CAPEX

-
RNAZ annual capital expenditures value is unknown

CAPEX 1-year change

-
RNAZ annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$18.11M
RNAZ annual free cash flow is -$18.11 million

Free cash flow 1-year change

-14.16%
RNAZ annual free cash flow is down -14.16% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
RNAZ annual gross profit margin value is unknown

Operating margin

-
RNAZ annual operating profit margin value is unknown

Net margin

-
RNAZ annual net profit margin value is unknown

ROA & ROE

ROA

-358.75%
RNAZ annual return on assets is -358.75%

ROE

-1130.31%
RNAZ annual return on equity is -1130.31%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
RNAZ price to earnings ratio value is unknown

PE ratio Sector rank

-
RNAZ price to earnings ratio is unknown

PB Ratio

PB ratio

0.17
RNAZ price to book ratio is 0.17

PB ratio Sector rank

18.67%
RNAZ price to book ratio is higher than 18.67% of companies in Healthcare sector

PS Ratio

PS ratio

-
RNAZ price to sales ratio value is unknown

PS ratio Sector rank

-
RNAZ price to sales ratio is unknown

Enterprise value

Enterprise value

-$1.44M
RNAZ enterprise value is -$1.44 million

Enterprise value Sector rank

9.41%
RNAZ enterprise value is higher than 9.41% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

0.10
RNAZ EV/EBITDA is 0.10

EV/EBITDA Sector rank

66.99%
RNAZ EV/EBITDA is higher than 66.99% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

1.28
RNAZ annual current ratio is 1.28

Quick ratio

-
RNAZ annual quick ratio value is unknown

Leverage

Debt to equity

0.27
RNAZ annual debt to equity ratio is 0.27

Interest coverage ratio

-330.77
RNAZ annual interest coverage ratio is -330.77

Risk & Stability

Piotroski F-Score

-
RNAZ piotroski f-score value is unknown

Altman Z-Score

-
RNAZ altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Mar 13, 25 HC Wainwright & Co.
Buy
Feb 7, 25 HC Wainwright & Co.
Buy
Feb 6, 25 HC Wainwright & Co.
Buy
Dec 18, 24 HC Wainwright & Co.
Buy
Nov 15, 24 HC Wainwright & Co.
Buy
Oct 24, 24 HC Wainwright & Co.
Buy
Sep 6, 24 HC Wainwright & Co.
Buy
Aug 15, 24 HC Wainwright & Co.
Buy
May 29, 24 HC Wainwright & Co.
Buy
May 16, 24 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

CYTO logo
Altamira Therapeutics (CYTO)
VRPX logo
Virpax Pharmaceuticals (VRPX)
KRBP logo
Kiromic BioPharma (KRBP)
CUTR logo
Cutera (CUTR)
IMAC Holdings (BACK)
TCBP logo
TC Biopharm (Holdings) (TCBP)
HEPA logo
Hepion Pharmaceuticals (HEPA)
TCON logo
TRACON Pharmaceuticals (TCON)
SRNE logo
Sorrento Therapeutics (SRNE)
  • What is the ticker symbol for TransCode Therapeutics?
  • Does TransCode Therapeutics pay dividends?
  • What sector is TransCode Therapeutics in?
  • What industry is TransCode Therapeutics in?
  • What country is TransCode Therapeutics based in?
  • When did TransCode Therapeutics go public?
  • Is TransCode Therapeutics in the S&P 500?
  • Is TransCode Therapeutics in the NASDAQ 100?
  • Is TransCode Therapeutics in the Dow Jones?
  • When was TransCode Therapeutics's last earnings report?
  • When does TransCode Therapeutics report earnings?
  • Should I buy TransCode Therapeutics stock now?

What is the ticker symbol for TransCode Therapeutics?

The ticker symbol for TransCode Therapeutics is NASDAQ:RNAZ

Does TransCode Therapeutics pay dividends?

No, TransCode Therapeutics does not pay dividends

What sector is TransCode Therapeutics in?

TransCode Therapeutics is in the Healthcare sector

What industry is TransCode Therapeutics in?

TransCode Therapeutics is in the Biotechnology industry

What country is TransCode Therapeutics based in?

TransCode Therapeutics is headquartered in United States

When did TransCode Therapeutics go public?

TransCode Therapeutics's initial public offering (IPO) was on July 8, 2021

Is TransCode Therapeutics in the S&P 500?

No, TransCode Therapeutics is not included in the S&P 500 index

Is TransCode Therapeutics in the NASDAQ 100?

No, TransCode Therapeutics is not included in the NASDAQ 100 index

Is TransCode Therapeutics in the Dow Jones?

No, TransCode Therapeutics is not included in the Dow Jones index

When was TransCode Therapeutics's last earnings report?

TransCode Therapeutics's most recent earnings report was on May 16, 2022

When does TransCode Therapeutics report earnings?

The date for TransCode Therapeutics's next earnings report has not been announced yet

Should I buy TransCode Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page